Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients

Y. Wang, T. K. Choueiri, J. L. Lee, M. H. Tan, S. Y. Rha, S. A. North, C. K. Kollmannsberger, D. F. McDermott, D. Y.C. Heng

Research output: Contribution to journalArticle

14 Citations (Scopus)


Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. Methods: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose reductions and outcomes using the International mRCC Database Consortium. Results: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of dose modifications/reductions between non-Asians and Asians was similar (55% vs 61% P=0.1197). When adjusted for risk groups, there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months, P<0.0001; 22.6 vs 16.1 months, P=0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P=0.0028; 28.0 vs 18.7 months, P=0.0069, respectively). Conclusions: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to longer treatment durations, but direct comparisons are needed.

Original languageEnglish
Pages (from-to)1433-1437
Number of pages5
JournalBritish journal of cancer
Issue number6
Publication statusPublished - 2014 Mar 18

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients'. Together they form a unique fingerprint.

  • Cite this

    Wang, Y., Choueiri, T. K., Lee, J. L., Tan, M. H., Rha, S. Y., North, S. A., Kollmannsberger, C. K., McDermott, D. F., & Heng, D. Y. C. (2014). Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients. British journal of cancer, 110(6), 1433-1437.